A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years
Open Access
- 10 September 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 32 (4) , 708-717
Abstract
To analyse serious infection (SI) and herpes zoster-related disease (HZD) during long-term treatment of rheumatoid arthritis with the oral Janus kinase inhibitor, peficitinib (ASP015K). This was a post hoc analysis of pooled data from one Phase 2b study and two Phase 3 studies and final data from a long-term extension study of peficitinib in Asian rheumatoid arthritis patients. Two pooled datasets were analysed (Phase 3 studies and Phase 2/3 studies). Univariate and multivariate Cox regression analyses explored relationships between exposure-adjusted incidence rate of SI and HZD, peficitinib dose, and baseline factors. Total peficitinib exposure for 1052 patients receiving once-daily peficitinib in the pooled Phase 2/3 Asian studies was 2998.9 patient-years. Exposure-adjusted incidence rates (95% confidence interval) of SI and HZD were 2.7 (2.2, 3.4) and 6.9 (6.0, 8.0) per 100 patient-years, respectively, in pooled Phase 2/3 studies. Advanced age was prognostic for SI and HZD, while baseline prednisolone dose was prognostic for SI. There was no temporal relationship between either adverse event and prolonged peficitinib administration. As expected in this peficitinib-treated population, older patients had increased risk of SI and HZD, and those receiving higher prednisolone doses had increased risk of SI.Keywords
Funding Information
- Astellas Pharma Inc.
This publication has 30 references indexed in Scilit:
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb studyAnnals of the Rheumatic Diseases, 2016
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Systematic review of incidence and complications of herpes zoster: towards a global perspectiveBMJ Open, 2014
- The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) databaseRheumatology International, 2014
- Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse eventsRheumatology, 2014
- Incidence and Time Trends of Herpes Zoster in Rheumatoid Arthritis: A Population‐Based Cohort StudyArthritis Care & Research, 2012
- Time‐dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritisArthritis Care & Research, 2012
- Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm SafetyThe Journal of Rheumatology, 2011
- The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United KingdomArthritis Care & Research, 2007
- Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based studyArthritis & Rheumatism, 2002